Allergists Seek to Bolster Adherence to Shots, Sublingual Drops Treatments
Two new studies highlight the challenges for patients in sticking with allergy shots or sublingual immunotherapy. Both studies add to arguments in favor of having frank discussions before selecting these options and of making it easier to complete those treatments. The International Forum of Allergy and Rhinology published two studies by Sandra Lin, MD, of the University of Wisconsin and colleagues that were based on the same search of published literature. The investigators started with a pool of 1596 abstracts and identified studies on how well people were able to continue with subcutaneous immunotherapy (SCIT) and with sublingual immunotherapy (SLIT).
@mithu In 26 of the studies, persistence rates ranged from 7.0% to 88.7%, and in 18 studies, adherence rates ranged from 9.6% to 97.0%. The researchers did not conduct a meta-analysis, owing to the great variation in the design of the studies.